Printer Friendly

SOMATIX REPORTS THIRD QUARTER RESULTS

 SOMATIX REPORTS THIRD QUARTER RESULTS
 ALAMEDA, Calif., May 4 /PRNewswire/ -- Somatix Therapy Corp.


(NASDAQ: SOMA) today reported that third quarter losses for the period ended March 31, 1992 were $35,824,000. This included a one-time write-off of $33,104,000 for in-process technology as a result of the Company's merger with GeneSys Therapeutics Corp., a privately held gene therapy company. As earlier projected, the company posted no revenues for the period, having discontinued its contract manufacturing operations in November 1991. In the same period last year, the company was still actively engaged in contract manufacturing activities and posted revenues of $800,000.
 David Carter, chief executive officer, stated, "Without the one- time write-off for the GeneSys acquisition, the loss for the third quarter would have been $2,720,000. For the same period last year, eliminating a similar write-off of $19,381,000 for the merger between Hana Biologics, Inc. and Somatix Corp., the loss was $1,474,000."
 For the nine month period ended March 31, 1992, the Company posted a net loss of $40,553,000, including the $33,104,000 charge for the acquisition of GeneSys. The net loss for the comparable period the prior year was $23,974,000. If the numbers for both periods are adjusted to eliminate the technology write-offs, the losses for the first nine months of 1992 are $7,449,000 versus $4,593,000 for the same period in 1991. The major difference in these numbers is due to contract manufacturing revenues and fluctuations in interest income.
 Somatix completed a public equity offering during the third quarter of fiscal 1992, raising $36,065,000, after commissions and expenses, by issuing 3,450,000 shares of common stock at $11.50 per share.
 According to Carter, "This quarter included two major events for the company. The first was the completion of the GeneSys acquisition. This transaction brought significant research and proprietary assets to the company, including, what we believe to be, the most advanced gene therapy research for treating central nervous system diseases. It also strengthened Somatix's management team by adding Harry Hixson, Ph.D., formerly of Amgen, as the chairman of the board of directors. Finalizing the merger, coupled with the funds raised during our recent public offering gives Somatix the scientific and economic resources to pursue the commercialization of our programs. We anticipate development expenses to significantly increase in the future as we prepare to initiate clinical trials."
 Somatix Therapy Corp. is a leader in the development of gene therapy, a novel approach to the treatment of disease in which genes are inserted into a patient's cells to induce these cells to produce therapeutic proteins. Somatix is applying its gene therapy expertise to the research and development of new treatments for cancer, central nervous system diseases and hemophilia.
 SOMATIX THERAPY RESULTS
 Third Quarter Ended March 31 1992 1991
 Contract Manufacturing
 Revenues $ 0 $ 800,000
 Costs and Expenses 2,884,000 2,433,000
 Write-Off of Acquired
 In-Process Technology 33,104,000 19,381,000
 Operating Loss (35,988,000) (21,014,000)
 Other Income, Net 164,000 159,000
 Net Loss $ (35,824,000) $(20,855,000)
 Net Loss Per Share $ (3.32) $ (8.54)
 Shares Used in Calculation of
 Net Loss Per Share 10,792,860 2,443,259
 Nine Months Ended March 31 1992 1991
 Contract Manufacturing
 Revenues $ 69,000 $ 2,462,000
 Costs and Expenses 7,843,000 7,717,000
 Write-Off of Acquired
 In-Process Technology 33,104,000 19,381,000
 Operating Loss (40,878,000) (24,636,000)
 Other Income, Net 325,000 662,000
 Net Loss $(40,553,000) $(23,974,000)
 Net Loss Per Share $ (4.55) $ (12.08)
 Shares Used in Calculation of
 Net Loss Per Share 8,904,306 1,984,991
 -0- 5/4/92
 /CONTACT: Julie Wood of Somatix Therapy Corp., 510-748-3082/
 (SOMA) CO: Somatix Therapy Corp. ST: California IN: MTC SU: ERN


JL -- SF011 -- 6272 05/04/92 17:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:664
Previous Article:INTERVIEW/DEMONSTRATION OPPORTUNITY: INTERACTIVE TELEVISION INDUSTRY UNDERGOING MAJOR CHANGES
Next Article:DEL-VAL FINANCIAL ANNOUNCES THE COMPLETION OF SETTLEMENT AND RESTRUCTURING OF TWO DEBTS TOTALLING $21.2 MILLION


Related Articles
SOMATIX REPORTS THIRD QUARTER RESULTS
SOMATIX RECEIVES EXCLUSIVE WORLDWIDE LICENSE ON CANCER GENE THERAPY PATENT APPLICATION
SOMATIX REPORTS YEAR-END RESULTS
SOMATIX REPORTS FIRST QUARTER RESULTS
SOMATIX REPORTS SECOND QUARTER RESULTS
SOMATIX REPORTS THIRD QUARTER RESULTS
Somatix Reports Fiscal 1997 Second Quarter Results
Somatix Reports Third Quarter Fiscal 1997 Results
Cell Genesys/Somatix Merger Completed
Cell Genesys Reports Third Quarter Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters